NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has announced positive results from its Phase 2a clinical trial of NEO100, a drug candidate for recurrent brain cancer. The data, covered by Stonegate Capital Partners, shows that NEO100 met its primary endpoint, with a six-month progression-free survival (PFS) rate of 48.9% by RANO 2.0 criteria using Kaplan-Meier estimation, compared to a pre-specified 20% benchmark (p=0.0047). Median overall survival (OS) reached 26.09 months, and no major toxicities were reported.
The significance of these findings lies in the context of current treatment options. Management noted that salvage therapy for recurrent brain cancer typically offers 6-9 months of survival. The observed median OS of over two years suggests a substantial improvement, though confirmation in a randomized study is needed. The survival signal is considered the more critical readout, and the favorable tolerability profile supports the potential for chronic, patient-friendly treatment.
This readout moves NEO100 into a potential registrational program. The company intends to request a Type B meeting with the FDA to determine the design, endpoints, and approval pathway for a registrational trial. Regulatory alignment is now the key near-term catalyst, as it will clarify the path to potential approval.
Additionally, NeOnc's second clinical program, NEO212, has gained regulatory momentum. It received Phase 2 CMC clearance and FDA feedback indicating a potential accelerated approval pathway. This expands the company's pipeline beyond a single asset, with NEO100 also being explored in meningioma and pediatric brain tumors.
Financially, the company's R&D expenses increased to $2.6 million in the second quarter of fiscal 2026, up from $0.7 million year-over-year, reflecting expanded development activities. While funding remains important as the pipeline grows, the positive clinical data and regulatory progress enhance the company's optionality.
The full announcement, including downloadable images and more details, is available at [Stonegate Capital Partners' website](http://stonegateinc.com).
Investors and patients alike will be watching for the outcome of the FDA meeting, which could significantly impact the future of NEO100 and the broader brain cancer treatment landscape.
